CAMBRIDGE, Mass., Dec. 16 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) announced today that Whaijen Soo, M.D., Ph.D. has
been appointed Senior Vice President, Medical Research. Dr. Soo will oversee
all medical research activities, and he will also serve as a member of the
Research and Development management team. He reports to Dr. Burt Adelman,
Executive Vice President, Research and Development.
"As Biogen prepares to celebrate its 25 years as a biotechnology pioneer,
Dr. Soo's addition will help the organization to continue to deliver on the
promise of world-class drug discovery," said Dr. Adelman. "Dr. Soo brings
considerable medical research and clinical management expertise to this
position, in which he will contribute greatly to Biogen's efforts to develop
life-changing medicines for people throughout the world."
Dr. Soo joins Biogen following a distinguished 17-year career with Roche
Global Development, where he most recently served as Vice President, Clinical
Sciences and was responsible for global strategic planning. During his tenure
with Roche, Soo headed the oncology, virology and transplant areas and built
Roche's genomics and bioinformatics capabilities. In addition, Soo was
responsible for the integration of diagnostics with pharmaceutical business
strategy.
During his career with Roche, Soo was instrumental in making AIDS a
treatable disease by developing medicines that have reduced AIDS mortality by
90 percent. Soo also held several positions with Roche, including Research
Physician Section Head, Assistant Vice President and Global Therapeutic Area
Head, and Vice President, Virology and Immunology, Global Clinical Research.
Dr. Soo earned a B.S. in Chemistry from the National Taiwan University and
graduated with a Ph.D. in Biochemistry from the University of California at
Berkeley. He attended the University of California at San Francisco Medical
School and performed his residency in Internal Medicine at Brigham and Woman's
Hospital, Harvard Medical School.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and worldwide sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.Biogen.com.
Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
Tel: (617) 914-6524
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2812
SOURCE Biogen, Inc
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Media Contact, Amy McKnight, Associate
Director, Public Affairs, +1-617-914-6524, or Investment
Community Contact, Christina Dillon, Manager, Investor Relations,
+1-617-679-2812 both of Biogen, Inc.
|
